UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells - PubMed (original) (raw)
UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells
Claire L Sutherland et al. J Immunol. 2002.
Abstract
The UL16-binding proteins (ULBPs) are a novel family of MHC class I-related molecules that were identified as targets of the human CMV glycoprotein, UL16. We have previously shown that ULBP expression renders a relatively resistant target cell sensitive to NK cytotoxicity, presumably by engaging NKG2D, an activating receptor expressed by NK and other immune effector cells. In this study we show that NKG2D is the ULBP counterstructure on primary NK cells and that its expression is up-regulated by IL-15 stimulation. Soluble forms of ULBPs induce marked protein tyrosine phosphorylation, and activation of the Janus kinase 2, STAT5, extracellular signal-regulated kinase, mitogen-activated protein kinase, and phosphatidylinositol 3-kinase (PI 3-kinase)/Akt signal transduction pathways. ULBP-induced activation of Akt and extracellular signal-regulated kinase and ULBP-induced IFN-gamma production are blocked by inhibitors of PI 3-kinase, consistent with the known binding of PI 3-kinase to DAP10, the membrane-bound signal-transducing subunit of the NKG2D receptor. While all three ULBPs activate the same signaling pathways, ULBP3 was found to bind weakly and to induce the weakest signal. In summary, we have shown that NKG2D is the ULBP counterstructure on primary NK cells and for the first time have identified signaling pathways that are activated by NKG2D ligands. These results increase our understanding of the mechanisms by which NKG2D activates immune effector cells and may have implications for immune surveillance against pathogens and tumors.
Similar articles
- Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A, Mousavi-Jazi M, Eriksson M, Odeberg J, Söderberg-Nauclér C, Cosman D, Kärre K, Cerboni C. Rölle A, et al. J Immunol. 2003 Jul 15;171(2):902-8. doi: 10.4049/jimmunol.171.2.902. J Immunol. 2003. PMID: 12847260 - The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.
Sutherland CL, Chalupny NJ, Cosman D. Sutherland CL, et al. Immunol Rev. 2001 Jun;181:185-92. doi: 10.1034/j.1600-065x.2001.1810115.x. Immunol Rev. 2001. PMID: 11513139 Review. - ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.
Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. Cosman D, et al. Immunity. 2001 Feb;14(2):123-33. doi: 10.1016/s1074-7613(01)00095-4. Immunity. 2001. PMID: 11239445 - Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H, Kim J, Cosman D, Choi I. Song H, et al. Cell Immunol. 2006 Jan;239(1):22-30. doi: 10.1016/j.cellimm.2006.03.002. Epub 2006 Apr 21. Cell Immunol. 2006. PMID: 16630603 - UL16 binding proteins.
Cao W, He W. Cao W, et al. Immunobiology. 2004;209(3):283-90. doi: 10.1016/j.imbio.2004.04.008. Immunobiology. 2004. PMID: 15518340 Review.
Cited by
- Comprehensive Insight into the Functional Roles of NK and NKT Cells in HTLV-1-Associated Diseases and Asymptomatic Carriers.
Mahdifar M, Boostani R, Taylor GP, Rezaee SA, Rafatpanah H. Mahdifar M, et al. Mol Neurobiol. 2024 Oct;61(10):7877-7889. doi: 10.1007/s12035-024-03999-8. Epub 2024 Mar 4. Mol Neurobiol. 2024. PMID: 38436833 Review. - Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: a systematic review of clinical trials evidence from solid and hematological tumors.
Alotaibi F, Alshammari K, Alotaibi BA, Alsaab H. Alotaibi F, et al. Front Pharmacol. 2024 Jan 9;14:1280591. doi: 10.3389/fphar.2023.1280591. eCollection 2023. Front Pharmacol. 2024. PMID: 38264532 Free PMC article. - Breakthrough of solid tumor treatment: CAR-NK immunotherapy.
Wang W, Liu Y, He Z, Li L, Liu S, Jiang M, Zhao B, Deng M, Wang W, Mi X, Sun Z, Ge X. Wang W, et al. Cell Death Discov. 2024 Jan 20;10(1):40. doi: 10.1038/s41420-024-01815-9. Cell Death Discov. 2024. PMID: 38245520 Free PMC article. Review. - Structures of liganded glycosylphosphatidylinositol transamidase illuminate GPI-AP biogenesis.
Xu Y, Li T, Zhou Z, Hong J, Chao Y, Zhu Z, Zhang Y, Qu Q, Li D. Xu Y, et al. Nat Commun. 2023 Sep 8;14(1):5520. doi: 10.1038/s41467-023-41281-y. Nat Commun. 2023. PMID: 37684232 Free PMC article. - Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
Zhang M, Lam KP, Xu S. Zhang M, et al. Front Immunol. 2023 Aug 9;14:1207276. doi: 10.3389/fimmu.2023.1207276. eCollection 2023. Front Immunol. 2023. PMID: 37638058 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous